Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Deferred Tax Assets: 2013-2014

Historic Current Deferred Tax Assets for Amphastar Pharmaceuticals (AMPH) over the last 2 years, with Dec 2014 value amounting to $19.5 million.

  • Amphastar Pharmaceuticals' Current Deferred Tax Assets rose 19.14% to $19.2 million in Q3 2015 from the same period last year, while for Sep 2015 it was $19.2 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of $19.5 million for FY2014, which is 21.35% up from last year.
  • As of FY2014, Amphastar Pharmaceuticals' Current Deferred Tax Assets stood at $19.5 million, which was up 21.35% from $16.1 million recorded in FY2013.
  • In the past 5 years, Amphastar Pharmaceuticals' Current Deferred Tax Assets ranged from a high of $19.5 million in FY2014 and a low of $16.1 million during FY2013.
  • Moreover, its 2-year median value for Current Deferred Tax Assets was $17.8 million (2013), whereas its average is $17.8 million.
  • Data for Amphastar Pharmaceuticals' Current Deferred Tax Assets shows a peak YoY rose of 21.35% (in 2014) over the last 5 years.
  • Yearly analysis of 2 years shows Amphastar Pharmaceuticals' Current Deferred Tax Assets stood at $16.1 million in 2013, then climbed by 21.35% to $19.5 million in 2014.